Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Active funds frequently lag behind due to fees and manager risk, while index funds provide broad exposure with lower costs and smoother performance.
22,822 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Lawmakers warn that granting a national bank charter to a crypto-focused issuer could undermine financial integrity a...
A biotech stock that jumped 360% for investors is dealing with a big fund trim while staying the largest holding. Thi...
As the U.S. ramps up nuclear capacity, one stock could benefit from policy shifts, domestic fuel security, and growin...
The market tops can be unsettling, but smart growth ideas endure. This guide highlights three compelling picks—Visa, ...
Energy markets swing on geopolitics and supply, but a well-chosen integrated energy stock hold can deliver steady div...
Investors cheered a strong tesla quarterly deliveries jump, yet the stock traded lower. This article unpacks the reas...
Trilogy Metals has fallen hard this week, leaving investors asking whether the downturn is a short-lived pullback or ...
Arm Holdings sits at the crossroads of mobile silicon and AI at the edge. This article lays out why edge AI could ext...
Costco's stock keeps breaking the $1,000 threshold, fueling split rumors. This guide unpacks why the price stays high...
Bank of America finished the Fed stress tests without a dividend hike while peers boosted payouts. Here’s what the ba...
Analysts say the doom loop helps explain why the global economy is growing bleaker in 2026. High borrowing costs, wea...